NFKB1 and pancreatic neoplasm: We previously reported that nafamostat mesilate, a synthetic serine protease inhibitor, inhibited gemcitabine-induced activation of NF-κB and increased chemosensitivity to gemcitabine and cell apoptosis in pancreatic cancer [12].